JAGX - Jaguar Health, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Francisco,
United States
Type: Equity
JAGX price evolution
JAGX
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $10.56 | $9.01 | $17.46 | $17.05 |
| Short term investments | ||||
| Net receivables | $2.46 | $2.08 | $2.25 | $2.14 |
| Inventory | $6.6 | $6.75 | $4.88 | $4.9 |
| Total current assets | $25.21 | $23.36 | $28.47 | $28.43 |
| Long term investments | ||||
| Property, plant & equipment | $1.68 | $1.78 | $1.76 | $1.73 |
| Goodwill & intangible assets | $22.56 | $22.99 | $22.23 | $22.65 |
| Total noncurrent assets | $26.08 | $26.52 | $24.43 | $24.83 |
| Total investments | ||||
| Total assets | $51.29 | $49.88 | $52.91 | $53.27 |
| Current liabilities | ||||
| Accounts payable | $6.29 | $5.64 | $3.71 | $4.93 |
| Deferred revenue | ||||
| Short long term debt | $12.15 | $8.34 | $7.19 | $3.42 |
| Total current liabilities | $26.94 | $22.9 | $19.09 | $15.47 |
| Long term debt | $20.74 | $24.23 | $0.92 | $25.94 |
| Total noncurrent liabilities | $20.74 | $24.23 | $25.7 | $25.94 |
| Total debt | $32.9 | $32.57 | $8.11 | $29.36 |
| Total liabilities | $47.69 | $47.13 | $44.8 | $41.41 |
| Shareholders' equity | ||||
| Retained earnings | -$259.37 | -$246.85 | -$237.48 | -$219.49 |
| Other shareholder equity | ||||
| Total shareholder equity | $3.65 | $2.72 | $8.04 | $11.61 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $17.05 | $8.09 | $3.88 | $2.57 |
| Short term investments | ||||
| Net receivables | $2.14 | $4.56 | $1.69 | $1 |
| Inventory | $4.9 | $2.78 | $2.13 | $3.34 |
| Total current assets | $28.43 | $17.79 | $9.52 | $8.15 |
| Long term investments | ||||
| Property, plant & equipment | $1.73 | $0.68 | $1.26 | $0.76 |
| Goodwill & intangible assets | $22.65 | $24.34 | $26.02 | $31.71 |
| Total noncurrent assets | $24.83 | $25.05 | $26.89 | $32.89 |
| Total investments | ||||
| Total assets | $53.27 | $42.84 | $36.41 | $41.04 |
| Current liabilities | ||||
| Accounts payable | $4.93 | $4.76 | $5.35 | $5.41 |
| Deferred revenue | ||||
| Short long term debt | $3.42 | $3.79 | $7.12 | $16.08 |
| Total current liabilities | $15.47 | $13.22 | $15.39 | $26.66 |
| Long term debt | $25.94 | $12.42 | $0.45 | |
| Total noncurrent liabilities | $25.94 | $12.42 | $0.45 | |
| Total debt | $29.36 | $16.21 | $7.57 | $16.08 |
| Total liabilities | $41.41 | $25.64 | $15.84 | $26.66 |
| Shareholders' equity | ||||
| Retained earnings | -$219.49 | -$166.9 | -$133.09 | -$94.55 |
| Other shareholder equity | $11.61 | $9 | ||
| Total shareholder equity | $11.61 | $17.2 | $10.67 | $5.38 |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.15 | $2.92 | $2.63 | $2.08 |
| Cost of revenue | $0.61 | $0.46 | $0.46 | $0.47 |
| Gross Profit | $2.54 | $2.46 | $2.17 | $1.61 |
| Operating activities | ||||
| Research & development | $5.94 | $2.45 | $4.95 | $5.48 |
| Selling, general & administrative | $6.49 | $6.49 | $8.98 | $6.95 |
| Total operating expenses | $12.43 | $8.94 | $13.92 | $12.43 |
| Operating income | -$9.9 | -$6.48 | -$11.75 | -$10.82 |
| Income from continuing operations | ||||
| EBIT | -$9.88 | -$6.85 | -$13.97 | -$11.88 |
| Income tax expense | ||||
| Interest expense | $2.73 | $2.54 | $4.19 | $2.43 |
| Net income | ||||
| Net income | -$12.61 | -$9.39 | -$18.16 | -$14.32 |
| Income (for common shares) | -$12.52 | -$9.37 | -$17.99 | -$14.31 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4.33 | $9.38 | $5.78 | $4.42 |
| Cost of revenue | $2.33 | $3.28 | $3.82 | $2.77 |
| Gross Profit | $2 | $6.11 | $1.96 | $1.65 |
| Operating activities | ||||
| Research & development | $15.08 | $6.41 | $5.82 | $5.15 |
| Selling, general & administrative | $26 | $21 | $20.44 | $22.11 |
| Total operating expenses | $42.71 | $32.75 | $30.91 | $32.47 |
| Operating income | -$40.71 | -$26.65 | -$28.95 | -$30.82 |
| Income from continuing operations | ||||
| EBIT | -$44.18 | -$31.02 | -$32.8 | -$29.52 |
| Income tax expense | $0.01 | |||
| Interest expense | $8.42 | $2.79 | $5.73 | $2.63 |
| Net income | ||||
| Net income | -$52.6 | -$33.81 | -$38.54 | -$32.15 |
| Income (for common shares) | -$52.59 | -$38.65 | -$44.73 | -$32.15 |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$12.61 | -$9.39 | -$18.16 | -$14.32 |
| Operating activities | ||||
| Depreciation | $0.59 | $0.65 | $0.46 | $0.48 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.74 | $1.11 | $1.06 | $1.14 |
| Total cash flows from operations | -$8.53 | -$10.46 | -$7.7 | -$8.92 |
| Investing activities | ||||
| Capital expenditures | -$0 | |||
| Investments | $10.48 | |||
| Total cash flows from investing | -$0.06 | $10.48 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $6.22 | $2.45 | $3.23 | |
| Net borrowings | $3.88 | $0.66 | -$0.78 | -$0.35 |
| Total cash flows from financing | $10.15 | $3.25 | $8.15 | $3.12 |
| Effect of exchange rate | -$0.01 | $0.03 | ||
| Change in cash and equivalents | $1.55 | -$8.44 | $0.41 | $4.68 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$52.6 | -$33.81 | -$38.54 | -$32.15 |
| Operating activities | ||||
| Depreciation | $1.81 | $2.28 | $1.93 | $1.32 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $3.97 | $3.81 | $3.13 | $2.02 |
| Total cash flows from operations | -$34.97 | -$15.28 | -$20.46 | -$22.73 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.01 | -$0.01 | |
| Investments | ||||
| Total cash flows from investing | -$0.01 | -$0.01 | -$0.01 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $35.62 | $7.76 | $6.63 | $16.68 |
| Net borrowings | $8.11 | $12.06 | -$0.1 | $0.78 |
| Total cash flows from financing | $43.94 | $19.49 | $21.77 | $24.55 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $8.96 | $4.21 | $1.32 | $1.81 |
News
|
Why Evoqua Water Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In...
Investing.com
23 Jan 2023
|
|
Bed Bath & Beyond Leads Rout in Meme Stocks as Mania Fizzles
Bloomberg via Yahoo Finance
22 Aug 2022
|
|
Are Penny Stocks Worth Investing In This Month? 3 To Watch Under $1
St. Joseph News-Press
3 Apr 2022
|
|
53 Biggest Movers From Yesterday
Benzinga
1 Apr 2022
|
|
Here's Why Jaguar Health Shares Are Popping Off By Benzinga
Investing.com
31 Mar 2022
|
|
68 Biggest Movers From Yesterday
Benzinga
16 Mar 2022
|
|
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.82% By Investing.com
Investing.com
15 Mar 2022
|
|
3 Hard-Hit Tech Stocks Wall Street Predicts Will Rebound by 50% or More
Entrpreneur
2 Mar 2022
|
|
20 Stocks Moving in Thursday's Pre-Market Session
Benzinga
13 Jan 2022
|
|
Alternative Asset Management Firm TPG Launches IPO
Investopedia
13 Jan 2022
|
Fundamentals
| Market cap | $624.98M |
|---|---|
| Enterprise value | $647.32M |
| Shares outstanding | 137.96M |
| Revenue | $10.78M |
|---|---|
| EBITDA | -$40.42M |
| EBIT | -$42.59M |
| Net Income | -$54.48M |
| Revenue Q/Q | 400.00% |
| Revenue Y/Y | 123.01% |
| P/E ratio | -11.47 |
|---|---|
| EV/Sales | 60.07 |
| EV/EBITDA | -16.02 |
| EV/EBIT | -15.20 |
| P/S ratio | 58.00 |
| P/B ratio | 171.37 |
| Book/Share | 0.03 |
| Cash/Share | 0.08 |
| EPS | -$0.39 |
|---|---|
| ROA | -105.10% |
| ROE | -837.56% |
| Debt/Equity | 3.57 |
|---|---|
| Net debt/EBITDA | -0.92 |
| Current ratio | 0.94 |
| Quick ratio | 0.69 |